LifeMD, Inc.
6.15+0.01 (+0.16%)
Oct 28, 4:00:01 PM EDT · NasdaqGM · LFMD · USD
Key Stats
Market Cap
291.62MP/E (TTM)
-Basic EPS (TTM)
-0.20Dividend Yield
0%Recent Filings
8-K
Auditor switch amid control issues
LifeMD dismissed CBIZ CPAs as its independent auditor on August 15, 2025, after a brief four-month stint, and appointed PwC on August 18 for the 2025 fiscal year. No disagreements arose with CBIZ, but material weaknesses persist in IT general controls and business process reviews. This switch underscores ongoing internal control challenges. PwC brings fresh oversight.
8-K
LifeMD Q2 revenue beats
LifeMD reported Q2 2025 results on August 5, showing total revenue up 23% to $62.2 million, with telehealth surging 30% to $48.6 million and adjusted EBITDA jumping 223% to $7.1 million. The company launched a nationwide behavioral health service, acquired a women's health practice, and upgraded its LifeMD+ membership, while generating over $8 million in operating cash flow and fully repaying senior debt post-quarter. Yet full-year guidance dipped due to resolved Rex MD issues. Balance sheet strengthened with $36.2 million cash.
10-Q
Q2 FY2025 results
LifeMD's Q2 revenue climbed 23% year-over-year to $62.2M, driven by 30% telehealth growth to $48.6M, while WorkSimpli held steady at $13.7M; gross margins dipped to 88% from 90% amid higher shipping and consult fees. Operating loss narrowed sharply to $0.9M from $6.3M, thanks to disciplined expense control despite a 10% marketing ramp-up. Free cash flow turned positive at $5.1M (derived), bolstering $36.2M cash reserves. The April asset buy for women's health adds hormone therapy reach, yet regulatory hurdles in telehealth persist.
8-K
LifeMD names COO
LifeMD appointed Shayna Webb Dray as Chief Operating Officer effective March 27, 2025, promoting her from Senior VP of Operations where she scaled the weight management program and oversaw pharmacy and clinical ops. The move, announced July 31, 2025, pairs a $400,000 base salary with 100,000 RSUs vesting through 2028 and upon hitting $25M and $35M annualized EBITDA targets by end-2027. This internal rise signals operational sharpening amid growth. Yet vesting hinges on performance.
8-K
Annual meeting results approved
LifeMD, Inc. held its annual stockholder meeting on June 13, 2025, where shareholders elected seven directors—Justin Schreiber, Dr. Joseph V. DiTrolio, Roberto Simon, John R. Strawn, Jr., Dr. Joan LaRovere, William Febbo, and Dr. Calum MacRae—to serve until the next annual meeting, with votes for ranging from 16.8 million to 21.6 million amid 9.7 million broker non-votes. Stockholders also ratified CBIZ CPAs, P.C. as the independent auditor for the fiscal year ending December 31, 2025, with overwhelming support of 31.5 million votes for versus just 38 against. All proposals passed, signaling strong governance continuity.
IPO
Website
Employees
Sector
Industry
DOCS
Doximity, Inc.
66.48-2.02
DRIO
DarioHealth Corp.
15.33-0.42
HIMS
Hims & Hers Health, Inc.
47.12-1.11
HYDTF
Hydreight Technologies Inc
3.37-0.12
LVCE
LIVECARE INC
0.03+0.00
MGRX
Mangoceuticals, Inc.
2.07-0.07
MNDR
Mobile-health Network Solutions
2.98+0.04
OMDA
Omada Health, Inc.
26.78+0.36
TALK
Talkspace, Inc.
2.70-0.03
TDOC
Teladoc Health, Inc.
8.36-0.65